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Background
Major limb amputations are life altering events for patients. 
Beyond the deficits in form and function, there is a risk of 
significant post-amputation pain that can manifest itself in 
the weeks, months, and years following the amputation. This 
pain decreases quality of life, increases the risk of depres-
sion, negatively affects interpersonal relationships, and 
impacts the ability to return to work.1 It has been reported 
that 70%–80% of the greater than 2 million major limb 
amputees in the United States deal with chronic pain of vary-
ing etiologies.1,2 The commonly reported amputation-related 
pain etiologies can be categorized as residual limb pain 
(RLP), phantom limb pain (PLP), and neuroma pain.
RLP, commonly referred to as “stump pain,” is localized 
intense pain that impacts prosthetic use and is a frequent 
cause of revision surgery.3 There are several etiologies of 
RLP including organic causes such as soft tissue inflamma-
tion, infection, osteomyelitis, and heterotopic ossification, 
but symptomatic neuromas are most often the underlying 
cause. It is important to differentiate the etiology of RLP 
when recommending management. The mechanisms of 
PLP, or the perceived notion of pain in the amputated limb, 
are not entirely understood. However, both PLP and neu-
roma-related RLP are related to the transection of major 
nerves—a necessary step of any amputation. When a periph-
eral nerve is severed, it will invariably attempt to regener-
ate. Nerve regeneration is guided both by the intrinsic 
pathway in the nerve and by signals from the distal target 
that it innervates. When these distal targets are unavailable, 
as is the case with a major limb amputation, there is a greater 
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risk of aberrant and inappropriate axonal regeneration lead-
ing to the formation of amputation site neuromas.
A neuroma consists of uncontrolled axonal growth 
entwined with myofibroblasts, Schwann cells, and endothe-
lial cells. Up to 60% of patients with a nerve injury can 
develop a painful neuroma.4,5 Traditional amputation tech-
niques addressed major nerves with traction neurectomy at 
the time of limb amputation. In this technique, traction is 
applied to the nerve as it is transected as proximal as possible 
so that the severed end will retract under viable proximal soft 
tissue. Despite traction neurectomy being a standard part of 
amputation technique, amputation site pain and neuroma for-
mation are still a significant problem that impact overall 
quality of life after limb amputation.
The scope of this issue should not be underestimated. 
There are approximately 185,000 major limb amputations 
performed each year and approximately 2 million amputees 
currently living in the United States.6 This population is pro-
jected to rise to 3.6 million by 2050.7 Phantom limb pain and 
RLP following major amputations are unfortunately quite 
common, with a prevalence of at least 30%–50%.8 These 
numbers are likely under reported. Following major limb 
amputations, there is a 40%–50% reoperation rate, with neu-
romas being the second most common reason for 
reoperation.9,10Beyond the pain itself, neuromas often make 
the use of a prosthetic uncomfortable or intolerable, which 
impacts the functional quality of a patient’s life.6
As our understanding of the peripheral nervous system 
has improved, it has become clear that severed nerves will 
invariably attempt to regenerate from the site of neurectomy 
to reach a distal target.11 In the case of traditional amputa-
tion, no distal target is available, leaving a high risk situation 
for neuroma formation. This can have significant conse-
quences for both the peripheral and the central nervous sys-
tems, as patients can theoretically eventually develop 
centralization of their pain symptoms.6 Management of neu-
roma-associated pain is multifactorial. There can be several 
contributing factors including mechanical pain, centralized 
pain, depression and psychosocial issues. Surgical interven-
tion addresses the mechanical aspect of a patient’s pain.
With the substantial morbidity seen following major limb 
amputations secondary to neuroma pain, strategies are 
needed to both prevent and treat neuromas. Over 100 surgi-
cal techniques have been reported for the surgical treatment 
of neuromas, with no consensus on the best treatment. A 
comparative meta-analysis stratified patients into 5 groups 
according to the treatment they received: excision and trans-
position (63%), excision only (35%), excision and repair 
(20%), neurolysis and coverage (19%), and excision and cap 
(4%).12 This study concluded that surgical treatment resulted 
in a meaningful reduction in pain in 77% of the patients with 
no significant differences between surgical techniques. In 
stratified analysis for confounding variables, excision and 
transposition and neurolysis with coverage were statistically 
more effective when neuroma pain was present for greater 
than 24 months prior to surgery or when the patient had 
already had one or more prior operations compared to exci-
sion and repair or excision alone, respectively.12 These find-
ings suggest that surgery can be an effective intervention for 
the management of neuroma pain. However, there remains 
much room for improvement.
Clinical and anatomic applications of 
targeted muscle reinnervation
Targeted muscle reinnervation (TMR) offers a new approach 
to neuroma management—as a result a paradigm shift regard-
ing the surgical management of neuromas is currently taking 
place. It has been known for decades that placing a severed 
nerve end into muscle capitalizes on our understanding that 
microenvironment matters for nerve regeneration.13Placement 
of transected sensory nerves in muscle yields small, organ-
ized nerve fibers with no myofibroblasts, neuroma formation, 
or connections to the skin.13In TMR, this is taken a step fur-
ther and the severed nerves are coapted to end motor targets 
(the entry point of a nerve branch into muscle) of an inner-
vated muscle, giving the severed nerves analogous tissue and 
a functional target to reinnervate. In other words, TMR gives 
the regenerating fascicles “somewhere to go and something 
to do,” not just “somewhere to go.”14 TMR that is performed 
months to years after the index amputation surgery, when the 
patient has established neuroma pain, is referred to as “sec-
ondary” TMR. The successful clinical results seen with sec-
ondary TMR led to the development of “primary” TMR, 
performed at the time of limb amputation, in an effort to pre-
vent development of PLP and neuroma pain. The objectives 
of primary TMR are the prevention of symptomatic neuromas 
and PLP, while the objective of secondary TMR is the treat-
ment of symptomatic neuroma and PLP.
TMR in the upper limb
Introduced clinically in 2004, TMR was originally designed 
to improve prosthetic function after upper extremity amputa-
tion by innervating residual muscles to create additional 
electromyographic signals to operate a myoelectric prosthe-
sis.15 Substantial clinical success was demonstrated with 
several initial case reports.16–18Notably, the amplification of 
myoelectric signals for advanced bioprosthetic limbs in the 
upper extremity occurs regardless of the timing of TMR, that 
is, whether it is performed as primary or secondary TMR.18 
In addition to good functional outcomes, it was noted that 
many patients who underwent TMR had subjective improve-
ment in their pain.18 This led to studies investigating TMR as 
a clinical strategy to treat established neuromas of amputated 
limbs. TMR in the upper limb is now commonly employed 
to optimize control of myoelectric prostheses, but is also uti-
lized for prevention or treatment of neuroma pain.19–23 
Among patients with upper limb amputations, those with 
transradial amputations are most likely to report phantom 
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pain and the use of neuropathic pain medication.24 The spe-
cific nerve transfers for TMR in the upper limb may vary 
depending on the exact level of amputation and quality of the 
remaining soft tissue.21,25 In the initial description of TMR 
for shoulder disarticulation, a cadaveric dissection demon-
strated that the median, musculocutaneous, radial, and ulnar 
nerves could be identified several centimeters proximal to 
the glenohumeral joint.15 In addition, these nerves were able 
to reach the pectoralis motor targets (where the respective 
pectoral nerve branches are entering the muscle), and the 
segmental innervation of the pectoralis major proved to be 
favorable for TMR.15
TMR in the Lower Limb
TMR of the lower extremity is often performed in below 
knee and above knee amputations and is used to prevent or 
treat neuroma and PLP.18 Current mainstream lower extrem-
ity prosthetics do not require the myoelectric signals that 
their upper extremity counterparts do. Thus, performing 
TMR in the lower extremity, whether it be primary or sec-
ondary, is typically aiming to prevent and treat neuroma for-
mation and pain only.
An anatomic dissection series was recently performed to 
identify a roadmap for the identification of end motor targets 
for TMR in a below knee amputation.26 In this study, the 
major branch points of motor nerves and the motor entry 
points to the muscles of the leg were dissected in five cadaver 
specimens. This dissection series demonstrated that the tibi-
alis anterior and the extensor digitorum longus were both 
acceptable targets in the anterior compartment. The peroneus 
longus had the most optimal motor entry points in the lateral 
compartment. In the superficial posterior compartment, the 
gastrocnemius and soleus muscles were both acceptable tar-
gets. The flexor digitorum longus was considered the best 
target located in the deep posterior compartment of the lower 
leg. This study provided a helpful road map to locate motor 
entry points in which to perform TMR in the lower extremity 
and aid in intra-operative decision making.26
A similar anatomic dissection series was performed to 
identify motor targets in the setting of a transfemoral (“above-
knee”) amputation.27 Five lower limbs were dissected and the 
motor points of the 13 muscles of the thigh were assessed. At 
this level, the tibial and the common peroneal nerves are the 
main nerves to be transferred into motor end points of nearby 
muscles for TMR. In this dissection series, the motor points 
to the biceps femoris and the semimembranosus were found 
to be the most easily coapted to the common peroneal and 
tibial nerves, respectively. The motor end points were in close 
proximity to these nerves and consistently located over a 
smaller territory along the thigh. The gracilis, adductor lon-
gus, vastus lateralis and vastus intermedius were considered 
as alternative motor endpoints based on their proximity to the 
tibial and common peroneal nerves, but have more wide-
spread motor end point distributions. The other muscles of 
the thigh, notably the rectus femoris, sartorius, vastus media-
lis, adductor brevis and adductor magnus muscles had motor 
points removed from the tibial and the common peroneal 
nerves that would necessitate a more difficult nerve coapta-
tion. Therefore, these motor points are less ideal for TMR in 
a transfemoral amputation.27
Surgical technique
The amputation is performed per the surgeon’s preferred 
technique, accounting for soft tissue needs. Note that for sec-
ondary TMR cases, marking the site of any Tinel signs pre-
operatively may help to locate neuromas.21If the amputation 
is performed under tourniquet control, nerve stimulation to 
identify end motor targets should be performed within 20–
30 min for reliable stimulation. Otherwise, the tourniquet 
must be released both for the purpose of hemostasis as well 
as allowing sufficient time for the nerves to recover from the 
ischemic palsy for stimulation. The use of a hand-held nerve 
stimulator allows identification of motor nerve branches 
entering the target muscle, known as the “end motor targets.” 
When performing TMR, paralytic agents and nerve blocks 
should be avoided until the nerve transfers are completed. 
The major peripheral nerves are identified and transected, 
leaving a substantial length to later perform TMR. 
Significantly more length needs to be left on the proximal 
nerves compared to a traditional amputation as the length is 
needed to facilitate the nerve transfer component of TMR. 
End motor targets are identified on neighboring innervated 
yet now de-functioned muscles. Ideal muscles for TMR are 
those that have lost their insertion sites as part of the amputa-
tion procedure (“defunctioned”) or have function that is 
redundant and have a motor innervation point that is in close 
proximity to the donor nerve.22,25The major peripheral nerves 
that were previously transected are then coapted to the 
defunctioned muscle just proximal to the entry point of the 
motor branch into the muscle. End-to-end coaptation is per-
formed from the transected peripheral nerve stump to the 
recipient motor nerve branch, typically using 8-0 nylon 
epineurial sutures. Fibrin glue may be utilized to augment 
the nerve coaptation as well.25 If there is significant size dis-
crepancy, muscle surrounding the motor nerve recipient is 
dissected to create a cuff of muscle tissue around the nerve 
coaptation with 5-0 suture. This theoretically optimizes 
ingrowth of the nerve transfer into both the target motor 
nerve as well as directly neurotizing the muscle. Different 
combinations of nerve transfer have been described, but any 
combination of nerve transfers will provide the amputated 
nerve with a target muscle. This is uniformly how TMR is 
approached, and the technique can be applied at almost any 
level of amputation. Recent reports have even described this 
technique in digital amputation.28
For transradial amputations, TMR is typically performed 
for the median, ulnar and radial nerves. Common nerve trans-
fers for transradial amputation TMR are listed in Table 1. At 
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the transhumeral level, TMR is usually performed for the 
musculocutaneous, median, ulnar and radial nerves (Table 1). 
For shoulder disarticulations, or very proximal transhumeral 
amputations, the infraclavicular brachial plexus is exposed.21 
The cords of the brachial plexus can also be identified at this 
level. The specific nerve coaptations performed may vary at 
this level; see Table 1.
In below knee amputations, TMR is typically performed 
for the saphenous, sural, superficial and deep peroneal and 
the tibial nerves (Figure 1).29 The common nerve transfers 
performed for TMR in below knee amputations are summa-
rized in Table 2.29 In transfemoral amputations, TMR is usu-
ally performed for the tibial and common peroneal nerves. 
The posterior femoral cutaneous nerve may be coapted end-
to-side to the tibial nerve for sensory reinnervation, if 
desired.4The common nerve transfers performed for TMR in 
transfemoral amputations (Figure 2) are also summarized in 
Table 2.
Outcomes
Since its inception, the literature continues to demonstrate 
reliable improvement in outcomes with TMR related to both 
pain and function for patients requiring amputation. Souza 
et al.19 retrospectively evaluated the effect of TMR on resid-
ual neuroma pain in upper-extremity amputees. The primary 
purpose for TMR in this case series was improved myoelec-
tric control for shoulder disarticulations and transhumeral 
amputations. Of the 26 patients in this study, 15 had evidence 
of postamputation neuroma pain before undergoing TMR. 
Of these 15 patients with neuroma pain, 14 had complete 
resolution, and one patient had improvement, but not com-
plete resolution, of pain. The other 11 patients did not have 
any evidence of postamputation neuroma pain and remained 
free of neuroma pain after the procedure.19 A recent rand-
omized control trial assessed the effect of TMR on 28 ampu-
tees with established neuroma pain who were assigned 
randomly to standard treatment with traction neurectomy or 
TMR.14 This study demonstrated a trend toward reduced 
RLP in the TMR group. Phantom limb pain scores were sig-
nificantly better in the TMR group compared to traction neu-
rectomy group. Results from this study also suggested that 
earlier (i.e. primary) TMR may be more effective in the pre-
vention and treatment of neuropathic pain.14
Valerio et al.30 performed a multi-institutional cohort 
study to assess the preemptive treatment of PLP and RLP 
Table 1. Recipient motor branches frequently utilized for targeted muscle reinnervation for each major nerve of the upper extremity 
by amputation level.
Donor nerve Recipient motor nerve branches
Transradial amputations
Median nerve Flexor digitorum superficialis, flexor digitorum profundus, brachioradialis, extensor 
carpi radialis longus, flexor capri radialis, palmaris longus
Ulnar nerve Flexor carpi ulnaris, flexor pollicis longus, extensor carpi radialis brevis, palmaris longus
Superficial radial nerve Flexor digitorum profundus
Transhumeral amputations
Median nerve Short head of biceps
Ulnar nerve Brachialis
Radial nerve Lateral head of the triceps
Shoulder disarticulation
Musculocutaneous nerve Clavicular head of pectoralis major
Median nerve Segment of sternal head of pectoralis major
Ulnar nerve Segment of sternal head of pectoralis major
Radial nerve Thoracodorsal nerve
Figure 1. Intra-operative photo demonstrating the saphenous, 
sural, tibial, deep peroneal (DPN), and superficial peroneal (SPN) 
nerves in a below knee amputation prior to targeted muscle 
reinnervation.
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with TMR at the time of major limb amputation. Fifty-one 
patients undergoing immediate TMR were compared with 
438 unselected major limb amputees. This cohort study dem-
onstrated lower rates of PLP in the TMR group compared to 
the control group. Patient-Reported Outcomes Measurement 
Information System (PROMIS) scores were lower in the 
TMR group for PLP, pain behavior, pain interference and 
RLP. There were significant improvements in numerical rat-
ing scale pain scores as well. The TMR group also demon-
strated a reduction in the use of opioid medications. The 
authors of this study recommended strong consideration of 
primary TMR to reduce pathologic PLP and symptomatic 
neuroma-related RLP.30
Bowen and colleagues performed TMR on 22 below knee 
amputations: 18 primary and 4 secondary amputations.29 No 
patients developed symptomatic neuromas during the aver-
age follow up period of 18 months. In regard to PLP, 72% of 
patients in the primary amputation group experienced PLP in 
the first month, with an abrupt decline to 19% 3 months post-
operatively and 13% at 6 months. These rates of neuroma 
pain and PLP represented substantial improvement over the 
control rates at their institution with traditional amputation.29
Discussion
TMR is still a relatively new area of peripheral nerve sur-
gery, and many questions remain. The ideal time interval as 
well as the differences in outcomes of primary versus sec-
ondary TMR still need to be further elucidated. As the proce-
dure requires microsurgical nerve coaptation, it is often 
performed by a peripheral nerve surgeon. This may limit the 
applicability as a primary technique in many centers, due to 
the overall paucity of peripheral nerve surgeons. The exact 
groups of patients that will benefit most from the procedure 
also needs to be better defined. Although, it is highly possi-
ble that all patients would benefit from TMR, factors such as 
patient age and amputation level may come into play. 
Recently, a hind limb amputation model in rats has been 
developed for further study of neuroma prevention with 
TMR; in addition to an earlier study looking at the effects of 
TMR on neuromas in a rabbit rectus abdominis flap 
model.31,32 These models may serve as the basis for future 
clinical studies.
Alternative techniques for the management of neuroma 
pain in amputees have also been described, including regen-
erative peripheral nerve interface (RPNI).33 RPNI uses free 
muscle grafts as physiologic targets. A series of patients 
treated with RPNI for post-amputation neuroma pain included 
46 RPNIs in 16 patients. At 7.5-month follow-up, there was a 
71% reduction in neuroma pain and 53% reduction in PLP.33 
Table 2. Recipient motor branches frequently utilized for targeted muscle reinnervation for each major nerve of the lower extremity 
by amputation level.
Donor nerve Recipient motor nerve branches
Below knee amputations
Posterior tibial nerve Medial or lateral gastrocnemius, tibialis posterior, medial or lateral soleus
Deep peroneal nerve Tibialis anterior, peroneus longus or peroneus brevis, medial soleus
Superficial peroneal nerve Peroneus longus or peroneus brevis
Saphenous nerve Medial gastrocnemius, medial soleus or vastus medialis
Sural nerve Tibialis posterior or soleus
Transfemoral amputations
Common peroneal nerve Biceps femoris
Tibial nerve Semimembranosis
Posterior femoral cutaneous nerve Tibial nerve (end to side)
Figure 2. This patient with an above knee amputation is 
positioned prone for secondary targeted muscle reinnervation. 
The sciatic nerve will be divided into the tibial and common 
peroneal divisions and coapted to the nerves to the 
semimembranosus (SM) and biceps femoris (BF), respectively.
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There are similarities between TMR and RPNI, such as 
allowing for nerve regeneration into a functional target and 
creating a good environment for the nerve ending with cover-
age of the nerve end with muscle and stable soft tissue. 
However, further studies are needed to compare outcomes of 
TMR and how they relate to outcomes of RPNI. The use of 
acellular nerve allografts (ANA) as a cap to limit axon regen-
eration has also been investigated for the management of neu-
roma pain.34 Proof of concept was established in a rat model 
demonstrating that ANAs attached to the proximal end of an 
injured nerve limited axon growth in a controlled matter, 
resulting in a lack of neuroma formation. In addition, the 
extent of axon growth from the injured nerve into the ANA 
was dependent on the ANA length.34 Clinically, this would 
allow the surgeon to reliably terminate the axonal regenera-
tion from an injured nerve by selecting an appropriate length 
ANA. This provides a less technically challenging, but more 
costly option for neuroma management. However, this tech-
nique differs markedly from TMR and RPNI as it does not 
provide functional nerve receptors or motor targets.
There are several limitations to this review. Overall, TMR 
is still a very new technique—in its infancy stage. Therefore, 
there is only a small number of studies to draw conclusions 
from, mostly out of 1-2 centers that have the bulk of the 
experience with this technique. There is a need for further 
high level research and randomized controlled trials in this 
field. Currently, there is only one randomized clinical trial 
1(RCT) comparing TMR to the standard treatment of neu-
roma excision and burying into muscle.14 In addition, many 
specialties at virtually every major surgical center perform 
major limb amputation. Due to the scale of practice change 
that would occur with recommending TMR at the time of 
each primary limb amputation, there is a need for consistent 
high level evidence to support this practice. Further elucidat-
ing any differences in pain outcomes between the upper and 
lower extremities may also help answer the question of the 
role of primary TMR, as significantly more lower extremity 
amputations are performed compared to amputations in the 
upper extremity. Early studies seem to report higher percent-
ages of pain free patients undergoing upper extremity TMR 
when compared to studies reporting on lower extremity 
TMR. However, early results in both upper and lower 
extremities appear very promising.
Conclusion
These novel surgical techniques are revolutionizing the 
thought processes and outcomes for prevention and manage-
ment of amputation-related pain. TMR is an effective tech-
nique and represents a significant advance in the field of 
amputation surgery. It should be considered by all surgeons 
performing amputation surgery as it has the potential to pre-
vent the development of both PLP and RLP. This technique 
is gaining acceptance across a variety of amputation sites, 
residual limb levels and indications. The benefits of TMR 
are expected to impact many medical specialties.
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